Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889791331> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2889791331 endingPage "10506" @default.
- W2889791331 startingPage "10506" @default.
- W2889791331 abstract "10506 Background: Metastatic RB is associated with a poor prognosis. Previous small series suggested that intensified systemic chemotherapy with or without radiation therapy (RT) may improve outcomes in this population. COG opened this prospective, multi-institutional, international trial to study the effectiveness of this approach. Methods: Patients with regional extra-ocular RB (stage 2 or 3) were treated with 4 cycles of intensive conventional chemotherapy (vincristine 0.05 mg/kg/day, cisplatin 3.5 mg/kg/day, cyclophosphamide 65 mg/kg x 2 days, etoposide 4 mg/kg x 2 days) followed by involved-field RT (4500 cGy). Two strata of patients with metastatic RB [stage 4a: distant metastases not involving the central nervous system involvement (CNS); and stage 4b (CNS metastases)/trilateral RB)] were treated with 4 cycles of the same chemotherapy. Patients with ≥ partial response then received 1 cycle of high-dose carboplatin (Calvert formula with AUC = 7/day, maximum 16.7 mg/kg/day) on days -8 to -6, thiotepa (10 mg/kg/day), & etoposide (8.3 mg/kg/day) on days -5 to -3 with autologous hematopoietic stem cell rescue on day 0. Patients with metastatic RB who did not achieve an adequate response to chemotherapy also received RT. Results: Sixty subjects (20 in each stratum) were enrolled; 57 were eligible and included in the analyses (based on data current to June 30, 2016). Toxicity was significant as expected and there were 2 therapy related deaths. Event-free survival (EFS) at 36 months was 87.7% (90% CI 65.4 to 96.0%) for subjects with stage 2 or 3 disease, 79.3% (90% CI 54.2 to 91.6%) for subjects with stage 4a disease and 8.0% (90% CI 1.0 to 25.1%) for subjects with stage 4b/trilateral disease. The observed results significantly improved the EFS in each stratum compared with historical results used for planning the study. Conclusions: This is the first prospective, multi-institutional, international study to show that intensive multi-modality therapy is highly effective for patients with regional extra-ocular RB and metastatic RB not involving the CNS. More effective therapy is required for patients with CNS RB. Clinical trial information: NCT00554788." @default.
- W2889791331 created "2018-09-27" @default.
- W2889791331 creator A5006930070 @default.
- W2889791331 creator A5020074136 @default.
- W2889791331 creator A5021052212 @default.
- W2889791331 creator A5032013913 @default.
- W2889791331 creator A5032519145 @default.
- W2889791331 creator A5047847872 @default.
- W2889791331 creator A5051711134 @default.
- W2889791331 creator A5053244337 @default.
- W2889791331 creator A5068118481 @default.
- W2889791331 creator A5073085588 @default.
- W2889791331 creator A5083288793 @default.
- W2889791331 creator A5087593086 @default.
- W2889791331 creator A5090325707 @default.
- W2889791331 creator A5057588239 @default.
- W2889791331 date "2017-05-20" @default.
- W2889791331 modified "2023-10-10" @default.
- W2889791331 title "Intensive multi-modality therapy for extra-ocular retinoblastoma (RB): A Children's Oncology Group (COG) trial (ARET0321)." @default.
- W2889791331 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.10506" @default.
- W2889791331 hasPublicationYear "2017" @default.
- W2889791331 type Work @default.
- W2889791331 sameAs 2889791331 @default.
- W2889791331 citedByCount "20" @default.
- W2889791331 countsByYear W28897913312018 @default.
- W2889791331 countsByYear W28897913312019 @default.
- W2889791331 countsByYear W28897913312020 @default.
- W2889791331 countsByYear W28897913312021 @default.
- W2889791331 countsByYear W28897913312022 @default.
- W2889791331 countsByYear W28897913312023 @default.
- W2889791331 crossrefType "journal-article" @default.
- W2889791331 hasAuthorship W2889791331A5006930070 @default.
- W2889791331 hasAuthorship W2889791331A5020074136 @default.
- W2889791331 hasAuthorship W2889791331A5021052212 @default.
- W2889791331 hasAuthorship W2889791331A5032013913 @default.
- W2889791331 hasAuthorship W2889791331A5032519145 @default.
- W2889791331 hasAuthorship W2889791331A5047847872 @default.
- W2889791331 hasAuthorship W2889791331A5051711134 @default.
- W2889791331 hasAuthorship W2889791331A5053244337 @default.
- W2889791331 hasAuthorship W2889791331A5057588239 @default.
- W2889791331 hasAuthorship W2889791331A5068118481 @default.
- W2889791331 hasAuthorship W2889791331A5073085588 @default.
- W2889791331 hasAuthorship W2889791331A5083288793 @default.
- W2889791331 hasAuthorship W2889791331A5087593086 @default.
- W2889791331 hasAuthorship W2889791331A5090325707 @default.
- W2889791331 hasConcept C126322002 @default.
- W2889791331 hasConcept C141071460 @default.
- W2889791331 hasConcept C143998085 @default.
- W2889791331 hasConcept C2776694085 @default.
- W2889791331 hasConcept C2776755627 @default.
- W2889791331 hasConcept C2778119113 @default.
- W2889791331 hasConcept C2778239845 @default.
- W2889791331 hasConcept C2779429289 @default.
- W2889791331 hasConcept C2779968505 @default.
- W2889791331 hasConcept C2781451048 @default.
- W2889791331 hasConcept C2908647359 @default.
- W2889791331 hasConcept C71924100 @default.
- W2889791331 hasConcept C99454951 @default.
- W2889791331 hasConceptScore W2889791331C126322002 @default.
- W2889791331 hasConceptScore W2889791331C141071460 @default.
- W2889791331 hasConceptScore W2889791331C143998085 @default.
- W2889791331 hasConceptScore W2889791331C2776694085 @default.
- W2889791331 hasConceptScore W2889791331C2776755627 @default.
- W2889791331 hasConceptScore W2889791331C2778119113 @default.
- W2889791331 hasConceptScore W2889791331C2778239845 @default.
- W2889791331 hasConceptScore W2889791331C2779429289 @default.
- W2889791331 hasConceptScore W2889791331C2779968505 @default.
- W2889791331 hasConceptScore W2889791331C2781451048 @default.
- W2889791331 hasConceptScore W2889791331C2908647359 @default.
- W2889791331 hasConceptScore W2889791331C71924100 @default.
- W2889791331 hasConceptScore W2889791331C99454951 @default.
- W2889791331 hasIssue "15_suppl" @default.
- W2889791331 hasLocation W28897913311 @default.
- W2889791331 hasOpenAccess W2889791331 @default.
- W2889791331 hasPrimaryLocation W28897913311 @default.
- W2889791331 hasRelatedWork W1601338141 @default.
- W2889791331 hasRelatedWork W1610638040 @default.
- W2889791331 hasRelatedWork W1970709330 @default.
- W2889791331 hasRelatedWork W1982035381 @default.
- W2889791331 hasRelatedWork W2197560586 @default.
- W2889791331 hasRelatedWork W2357464014 @default.
- W2889791331 hasRelatedWork W2397108126 @default.
- W2889791331 hasRelatedWork W2399446920 @default.
- W2889791331 hasRelatedWork W42551882 @default.
- W2889791331 hasRelatedWork W4290257576 @default.
- W2889791331 hasVolume "35" @default.
- W2889791331 isParatext "false" @default.
- W2889791331 isRetracted "false" @default.
- W2889791331 magId "2889791331" @default.
- W2889791331 workType "article" @default.